Incyte (INCY) Current Deferred Revenue (2010 - 2016)
Incyte's (INCY) quarterly Current Deferred Revenue came in at $2.9 million in Q3 2016, down 77.69% YoY from $12.9 million in Q4 2015, and down 52.85% on a QoQ basis from $6.1 million in Q2 2016.
Incyte (INCY) Current Deferred Revenue (2010 - 2016) Analysis & Trends
Incyte (INCY) has 7 years of Current Deferred Revenue data on file, last reported at $2.9 million in Q3 2016.
- Quarterly Current Deferred Revenue fell 77.69% year-over-year to $2.9 million in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $2.9 million (down 77.69% YoY) and the FY2015 annual result came in at $12.5 million, down 2.86% from the prior year.
- Current Deferred Revenue declined to $2.9 million in Q3 2016, from $6.1 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $67.0 million in Q1 2012 to a low of $2.9 million in Q3 2016.
- A 5-year average of $27.3 million and a median of $12.9 million in 2014 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2012 — Current Deferred Revenue changed 0.0% — and 2013, when it plunged 80.49%.
- Tracing INCY's Current Deferred Revenue over 5 years: stood at $66.1 million in 2012, then sank by 80.49% to $12.9 million in 2013, then decreased by 0.08% to $12.9 million in 2014, then dropped by 2.86% to $12.5 million in 2015, then slumped by 77.08% to $2.9 million in 2016.
- The last three Current Deferred Revenue figures came in at $2.9 million (Q3 2016), $6.1 million (Q2 2016), and $9.3 million (Q1 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 2.87 Mn |
| Jun 30, 2016 | 6.08 Mn |
| Mar 31, 2016 | 9.30 Mn |
| Dec 31, 2015 | 12.51 Mn |
| Sep 30, 2015 | 12.86 Mn |
| Jun 30, 2015 | 12.86 Mn |
| Mar 31, 2015 | 12.86 Mn |
| Dec 31, 2014 | 12.88 Mn |
| Sep 30, 2014 | 12.88 Mn |
| Jun 30, 2014 | 12.89 Mn |
| Mar 31, 2014 | 12.89 Mn |
| Dec 31, 2013 | 12.89 Mn |
| Sep 30, 2013 | 25.50 Mn |
| Jun 30, 2013 | 39.03 Mn |
| Mar 31, 2013 | 52.55 Mn |
| Dec 31, 2012 | 66.08 Mn |
| Sep 30, 2012 | 66.97 Mn |
| Jun 30, 2012 | 66.98 Mn |
| Mar 31, 2012 | 66.98 Mn |
| Dec 31, 2011 | 66.97 Mn |